The purpose of this study was to compare the clinical effects of pemetrexed and docetaxel combined with cisplatin in the treatment of patients with non-small cell lung cancer.A total of 58 patients with non-small cell...The purpose of this study was to compare the clinical effects of pemetrexed and docetaxel combined with cisplatin in the treatment of patients with non-small cell lung cancer.A total of 58 patients with non-small cell lung cancer who were enrolled between January 2017 and January 2018 were enlisted into a randomized digital table.29 patients who have received treatment with combined pemetrexed and cisplatin were assigned to the pemetrexed group,whereas for the other 29 patients which were treated with docetaxel and cisplatin combined,were assigned to the docetaxel group to verify the calculated clinical treatment efficiency of the patients with non-small cell lung cancer,soluble vascular cell adhesion molecule 1(SVCAM-1),and activated leukocyte cell adhesion molecule-1(alCAM-1)concentrations and to evaluate the quality of life scores of the patients after half a year as well as the incidences of adverse reactions following the treatments provided.The differences in SVCAM-1 and alCAM-1 concentrations and incidence of adverse reactions in patients with non-small cell lung cancer in the docetaxel group as compared with patients in the pemetrexed group after the treatments were statistically significant(P<0.05)where the calculations were performed with data sets gathered from and between the two groups.In addition,SVCAM-1 and alCAM-1 concentrations in patients in both pemetrexed group and docetaxel group demonstrated significant differences in concentrations before and after the treatments were provided,P<0.05.The comparative studies of the effects of the treatments on the quality of life scores and clinical treatment efficiency between the two groups after half a year,P>0.05,demonstrated no analytical significance.Both pemetrexed combined with cisplatin and docetaxel in combination with cisplatin as forms of treatments demonstrated significant effects in patients with non-small cell lung cancer.However,based on our study,it was found that the combined treatment involving pemetrexed and cisplatin can further reduce adverse reactions and thus is worthy of clinical application.展开更多
Objective To provide theoretical basis for clinical treatment of patients with terminal non-small cell lung cancer through the analysis of the cost and adverse reactions of the joint treatment of icotinib and pemetrex...Objective To provide theoretical basis for clinical treatment of patients with terminal non-small cell lung cancer through the analysis of the cost and adverse reactions of the joint treatment of icotinib and pemetrexed combined with cisplatin.Methods The clinical data of the patients diagnosed with terminal non-small cell lung cancer were collected and analyzed according to different drug administration schedules(n=53 of each group).The efficacy,cost and adverse reactions were evaluated respectively,aiming to provide the pharmacoeconomic evidence for the clinical applications.Results and Conclusion There was no significant difference between the efficacy of the icotinib group and the pemetrexed combined with cisplatin group,but the cost of the icotinib group was much lower,and the adverse reactions such as leukopenia,anemia,vomiting and nausea were far fewer than those in the pemetrexed combined cisplatin group.Although the two methods have similar therapeutic effects,the icotinib group has lower cost and fewer adverse reactions.Thus,from the perspective of pharmacoeconomics,icotinib has its advantage over the traditional regimen on the treatment of terminal non-small cell lung cancer.展开更多
A clinical study of the efficacy of vinorelbine plus cisplatin regimen in the management of advanced NSCLC was performed in 35 patients. Five of the 35 patients failed to finish one cycle of chemotherapy with this reg...A clinical study of the efficacy of vinorelbine plus cisplatin regimen in the management of advanced NSCLC was performed in 35 patients. Five of the 35 patients failed to finish one cycle of chemotherapy with this regimen because of severe and intractable leukopenia or rapid progress of the disease. Tumor response and toxicity were evaluated in the remaining 30 cases. Results showed that, with this regimen, the objective response rate (CR+PR) was 46.7%. The most common toxicity was leukopenia; other side effects included alopecia, gastrointestinal reactions, slight and transient renal and hepatic impairment and peripheral neuropathy. It suggested that vinorelbine plus cisplatin is a safe and effective regimen in the management of advanced NSCLC.展开更多
Background:Many tumors are refractory to immune checkpoint inhibitors,but their combination with cytotoxics is expected to improve sensitivity.Understanding how and when cytotoxics best re-stimulate tumor immunity cou...Background:Many tumors are refractory to immune checkpoint inhibitors,but their combination with cytotoxics is expected to improve sensitivity.Understanding how and when cytotoxics best re-stimulate tumor immunity could help overcome resistance to immune checkpoint inhibitors.Methods:In vivo studies were performed in C57BL/6 mice grafted with immune-refractory LL/2 lung cancer model.A longitudinal immunomonitoring study on tumor,spleen,and blood after multiple treatments including Cisplatin,Pemetrexed,and anti-VEGF,either alone or in combination,was performed,spanning a period of up to 21 days,to determine the optimal time window during which immune checkpoint inhibitors should be added.Finally,an efficacy study was conducted comparing the antiproliferative performance of various schedules of anti-VEGF,Pemetrexed-Cisplatin doublet,plus anti-PD-1(i.e.,immunomonitoring-guided scheduling,concurrent dosing or a random sequence),as well as single agent anti-PD1.Results:Immunomonitoring showed marked differences between treatments,organs,and time points.However,harnessing tumor immunity(i.e.,promoting CD8 T cells or increasing the T CD8/Treg ratio)started on D7 and peaked on D14 with the anti-VEGF followed by cytotoxics combination.Therefore,a 14-day delay between anti VEGF/cytotoxic and anti-PD1 administration was considered the best sequence to test.Efficacy studies then confirmed that this sequence achieved higher antiproliferative efficacy compared to other treatment modalities(i.e.,-71%in tumor volume compared to control).Conclusions:Anti-VEGF and cytotoxic agents show time-dependent immunomodulatory effects,suggesting that sequencing is a critical feature when combining these agents with immune checkpoint inhibitors.An efficacy study confirmed that sequencing treatments further enhance antiproliferative effects in lung cancer models compared to concurrent dosing and partly reverse the resistance to cytotoxics and anti-PD1.展开更多
文摘The purpose of this study was to compare the clinical effects of pemetrexed and docetaxel combined with cisplatin in the treatment of patients with non-small cell lung cancer.A total of 58 patients with non-small cell lung cancer who were enrolled between January 2017 and January 2018 were enlisted into a randomized digital table.29 patients who have received treatment with combined pemetrexed and cisplatin were assigned to the pemetrexed group,whereas for the other 29 patients which were treated with docetaxel and cisplatin combined,were assigned to the docetaxel group to verify the calculated clinical treatment efficiency of the patients with non-small cell lung cancer,soluble vascular cell adhesion molecule 1(SVCAM-1),and activated leukocyte cell adhesion molecule-1(alCAM-1)concentrations and to evaluate the quality of life scores of the patients after half a year as well as the incidences of adverse reactions following the treatments provided.The differences in SVCAM-1 and alCAM-1 concentrations and incidence of adverse reactions in patients with non-small cell lung cancer in the docetaxel group as compared with patients in the pemetrexed group after the treatments were statistically significant(P<0.05)where the calculations were performed with data sets gathered from and between the two groups.In addition,SVCAM-1 and alCAM-1 concentrations in patients in both pemetrexed group and docetaxel group demonstrated significant differences in concentrations before and after the treatments were provided,P<0.05.The comparative studies of the effects of the treatments on the quality of life scores and clinical treatment efficiency between the two groups after half a year,P>0.05,demonstrated no analytical significance.Both pemetrexed combined with cisplatin and docetaxel in combination with cisplatin as forms of treatments demonstrated significant effects in patients with non-small cell lung cancer.However,based on our study,it was found that the combined treatment involving pemetrexed and cisplatin can further reduce adverse reactions and thus is worthy of clinical application.
文摘Objective To provide theoretical basis for clinical treatment of patients with terminal non-small cell lung cancer through the analysis of the cost and adverse reactions of the joint treatment of icotinib and pemetrexed combined with cisplatin.Methods The clinical data of the patients diagnosed with terminal non-small cell lung cancer were collected and analyzed according to different drug administration schedules(n=53 of each group).The efficacy,cost and adverse reactions were evaluated respectively,aiming to provide the pharmacoeconomic evidence for the clinical applications.Results and Conclusion There was no significant difference between the efficacy of the icotinib group and the pemetrexed combined with cisplatin group,but the cost of the icotinib group was much lower,and the adverse reactions such as leukopenia,anemia,vomiting and nausea were far fewer than those in the pemetrexed combined cisplatin group.Although the two methods have similar therapeutic effects,the icotinib group has lower cost and fewer adverse reactions.Thus,from the perspective of pharmacoeconomics,icotinib has its advantage over the traditional regimen on the treatment of terminal non-small cell lung cancer.
文摘A clinical study of the efficacy of vinorelbine plus cisplatin regimen in the management of advanced NSCLC was performed in 35 patients. Five of the 35 patients failed to finish one cycle of chemotherapy with this regimen because of severe and intractable leukopenia or rapid progress of the disease. Tumor response and toxicity were evaluated in the remaining 30 cases. Results showed that, with this regimen, the objective response rate (CR+PR) was 46.7%. The most common toxicity was leukopenia; other side effects included alopecia, gastrointestinal reactions, slight and transient renal and hepatic impairment and peripheral neuropathy. It suggested that vinorelbine plus cisplatin is a safe and effective regimen in the management of advanced NSCLC.
基金supported by A^(*)midex Foundation-initiative d’Excellence and the Aix-Marseille Université。
文摘Background:Many tumors are refractory to immune checkpoint inhibitors,but their combination with cytotoxics is expected to improve sensitivity.Understanding how and when cytotoxics best re-stimulate tumor immunity could help overcome resistance to immune checkpoint inhibitors.Methods:In vivo studies were performed in C57BL/6 mice grafted with immune-refractory LL/2 lung cancer model.A longitudinal immunomonitoring study on tumor,spleen,and blood after multiple treatments including Cisplatin,Pemetrexed,and anti-VEGF,either alone or in combination,was performed,spanning a period of up to 21 days,to determine the optimal time window during which immune checkpoint inhibitors should be added.Finally,an efficacy study was conducted comparing the antiproliferative performance of various schedules of anti-VEGF,Pemetrexed-Cisplatin doublet,plus anti-PD-1(i.e.,immunomonitoring-guided scheduling,concurrent dosing or a random sequence),as well as single agent anti-PD1.Results:Immunomonitoring showed marked differences between treatments,organs,and time points.However,harnessing tumor immunity(i.e.,promoting CD8 T cells or increasing the T CD8/Treg ratio)started on D7 and peaked on D14 with the anti-VEGF followed by cytotoxics combination.Therefore,a 14-day delay between anti VEGF/cytotoxic and anti-PD1 administration was considered the best sequence to test.Efficacy studies then confirmed that this sequence achieved higher antiproliferative efficacy compared to other treatment modalities(i.e.,-71%in tumor volume compared to control).Conclusions:Anti-VEGF and cytotoxic agents show time-dependent immunomodulatory effects,suggesting that sequencing is a critical feature when combining these agents with immune checkpoint inhibitors.An efficacy study confirmed that sequencing treatments further enhance antiproliferative effects in lung cancer models compared to concurrent dosing and partly reverse the resistance to cytotoxics and anti-PD1.
